Table of Content - Mr Vaccines Market

Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease. Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children.

Market Dynamics

Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period.

For instance, according to the World Health Organization (WHO), from January 2020 to April 2021, eight African nations experienced major measles outbreaks that affected tens of thousands of children, owing to delayed vaccination programs or low routine immunization coverage.

Key features of the study:

This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the MR vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market

Detailed Segmentation:

MR Vaccines Market, By Vaccine Brand:
- MR Vaccine
- MRBEV (BE LTD.)
MR Vaccines Market, By Distribution Channel:
- Public
- Private
MR Vaccines Market, By Region:
- Commonwealth of Independent States (CIS) Countries
  - By Country
    - Russia
    - Uzbekistan
    - Kazakhstan
    - Ukraine
    - Turkmenistan
    - Belarus
    - Armenia
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Honduras
    - Colombia
    - Peru
    - Chile
- Europe
  - By Country
    - Turkey
- Asia Pacific
  - By Country
    - Pakistan
    - Indonesia
    - Bangladesh
    - Philippines
    - Vietnam
    - Thailand
    - Myanmar
    - Malaysia
    - Cambodia
    - Nepal
    - Sri Lanka
    - Papua New Guinea
    - Mauritius
- Middle East
  - By Country
    - UAE
    - Israel
    - Iraq
    - Iran
    - Saudi Arabia
    - Jordan
    - Qatar
    - Oman
    - Syrian Arab Republic
- Africa
  - By Country/Region
    - Nigeria
    - Tanzania
    - Democratic Republic of Congo
    - Ethiopia
    - Kenya
    - South Africa
    - Egypt
    - Morocco
    - Ghana
    - Uganda
    - Burkina Faso
    - Angola
    - Algeria
    - Zimbabwe
    - Tunisia
    - Botswana
    - Libya
    - Namibia
Company Profiles
- PT Bio Farma*
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Bio-Manguinhos
- BE Vaccines
- Serum Institute of India
- Crucell Switzerland AG

“*” marked represents similar segmentation in other categories in the respective section.

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Vaccine Brand
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Therapy Assessment
- Disease Assessment
- Epidemiological Assessment
- Industry Assessment
MR Vaccines Market– Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
MR Vaccines Market, By Vaccine Brand, 2021 – 2028, (US$ Mn. and No. of Doses in Mn.)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2018 – 2028
  - Segment Trends
- MR Vaccine
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
- MRBEV (BE LTD.)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
MR Vaccines Market, By Distribution Channel, 2021 – 2028, (US$ Mn. and No. of Doses in Mn.)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2018 – 2028
  - Segment Trends
- Public
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
- Private
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
MR Vaccines Market, By Region, 2021 – 2028, (US$ Mn. and No. of Doses in Mn.)
- Introduction
  - Market Share Analysis, By Region, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, For Regions, 2018–2028
- Commonwealth of Independent States (CIS) Countries
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - Russia
    - Uzbekistan
    - Kazakhstan
    - Ukraine
    - Turkmenistan
    - Belarus
    - Armenia
- Latin America
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - Brazil
    - Mexico
    - Argentina
    - Honduras
    - Colombia
    - Peru
    - Chile
- Europe
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - Turkey
- Asia
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - Pakistan
    - Indonesia
    - Bangladesh
    - Philippines
    - Vietnam
    - Thailand
    - Myanmar
    - Malaysia
    - Cambodia
    - Nepal
    - Sri Lanka
    - Papua New Guinea
    - Mauritius
- Middle East
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - UAE
    - Israel
    - Iraq
    - Iran
    - Saudi Arabia
    - Jordan
    - Qatar
    - Oman
    - Syrian Arab Republic
- Africa
  - Market Size and Forecast, By Vaccine Brand, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
  - Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn. and No. of Doses in Mn.)
    - Nigeria
    - Tanzania
    - Democratic Republic of Congo
    - Ethiopia
    - Kenya
    - South Africa
    - Egypt
    - Morocco
    - Ghana
    - Uganda
    - Burkina Faso
    - Angola
    - Algeria
    - Zimbabwe
    - Tunisia
    - Botswana
    - Libya
    - Namibia
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
  - PT Bio Farma
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Bio-Manguinhos
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Crucell Switzerland AG
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - Serum Institute of India
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
  - BE Vaccines
    - Company Overview
    - Product Portfolio
    - Financial Overview
    - Key Highlights
    - Market Strategies
- Analyst Views
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 28 market data tables and 16 figures on "MR Vaccines Market” - Global forecast to 2028

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Table of Contents

Need a Custom Report?

EXISTING CLIENTELE